Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DIFLOXACIN IMPURITY G CRS (15MG)

DIFLOXACIN IMPURITY G CRS (15MG)

NA

DISCOVER
DIPHENOXYLATE FOR SYSTEM SUITABILITY CRS - * NARC (10 MG)

DIPHENOXYLATE FOR SYSTEM SUITABILITY CRS - * NARC (10 MG)

3810-80-8

DISCOVER
LEVONORGESTREL FOR SYSTEM SUITABILITY 1 CRS (10 MG)

LEVONORGESTREL FOR SYSTEM SUITABILITY 1 CRS (10 MG)

797-63-7

DISCOVER
MINOXIDIL FOR SYSTEM SUITABILITY CRS (10 MG)

MINOXIDIL FOR SYSTEM SUITABILITY CRS (10 MG)

38304-91-5

DISCOVER
MONTELUKAST RACEMATE CRS (0.1MG)

MONTELUKAST RACEMATE CRS (0.1MG)

577953-88-9

DISCOVER
MONTELUKAST SODIUM CRS (15 MG)

MONTELUKAST SODIUM CRS (15 MG)

151767-02-1

DISCOVER
MONTELUKAST FOR PEAK IDENTIFICATION CRS (20 MG)

MONTELUKAST FOR PEAK IDENTIFICATION CRS (20 MG)

151767-02-1

DISCOVER
MONTELUKAST DICYCLOHEXYLAMINECRS (150 MG)

MONTELUKAST DICYCLOHEXYLAMINECRS (150 MG)

NA

DISCOVER
NATEGLINIDE CRS (200 MG)

NATEGLINIDE CRS (200 MG)

105816-04-4

DISCOVER
LONG PEPPER FOR SYSTEM SUITABILITY HRS (600 MG)

LONG PEPPER FOR SYSTEM SUITABILITY HRS (600 MG)

NA

DISCOVER
DILTIAZEM IMPURITY F CRS (15 MG)

DILTIAZEM IMPURITY F CRS (15 MG)

NA

DISCOVER
NATEGLINIDE IMPURITY A CRS (15 MG)

NATEGLINIDE IMPURITY A CRS (15 MG)

06/05/7077

DISCOVER